Quick Answer
10x Genomics, Inc. reported Total Revenue of $642.82 million for fiscal year 2025.
10x Genomics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $642.82M +5.2% |
$610.78M -1.3% |
$618.73M +19.8% |
$516.41M +5.3% |
$490.49M +64.1% |
$298.85M +21.5% |
| Revenue (ASC 606) | $642.82M +5.2% |
$610.78M -1.3% |
$618.73M +19.8% |
$516.41M +5.3% |
$490.49M +64.1% |
$298.85M +21.5% |
| Net Income | -$43.54M +76.2% |
-$182.63M +28.4% |
-$255.10M -53.7% |
-$166.00M -185.1% |
-$58.22M +89.3% |
-$542.73M -1636.7% |
| Diluted EPS | -$0.35 +77.0% |
-$1.52 +30.3% |
-$2.18 -49.3% |
-$1.46 -175.5% |
-$0.53 +90.1% |
-$5.37 -571.2% |
| Total Assets | $1.04B +13.4% |
$918.64M -4.8% |
$965.14M -6.2% |
$1.03B +1.0% |
$1.02B +9.6% |
$929.34M +53.4% |
| Long-Term Debt | — | — | — | — | — | $0.00 -100.0% |
| Stockholders Equity | $796.33M +12.1% |
$710.13M -4.2% |
$741.04M -8.0% |
$805.74M -1.4% |
$817.57M +10.6% |
$739.07M +75.9% |
| Operating Income | -$60.98M +68.7% |
-$194.56M +26.7% |
-$265.33M -58.0% |
-$167.94M -221.4% |
-$52.25M +90.2% |
-$534.14M -1647.1% |
| Gross Profit | $443.88M +7.1% |
$414.48M +1.3% |
$409.31M +3.4% |
$396.02M -4.9% |
$416.40M +73.2% |
$240.38M +30.0% |
| Shares Outstanding | 127.69M +4.4% |
122.29M +2.7% |
119.10M +3.4% |
115.20M +2.4% |
112.51M +3.7% |
108.49M +12.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $149.00M | -1.7% | -13.8% |
| Revenue (ASC 606) | September 30, 2025 | $149.00M | -1.7% | -13.8% |
| Net Income | September 30, 2025 | -$27.47M | +23.2% | -179.5% |
| Diluted EPS | September 30, 2025 | -$0.22 | +26.7% | -178.6% |
| Total Assets | September 30, 2025 | $1.03B | +9.6% | +4.8% |
| Long-Term Debt | September 30, 2020 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $785.12M | +8.6% | +1.5% |
| Operating Income | September 30, 2025 | -$32.24M | +22.3% | -207.0% |
| Gross Profit | September 30, 2025 | $100.31M | -5.7% | -19.8% |
| Shares Outstanding | March 31, 2021 | 109.59M | +11.7% | +1.0% |
- 10x Genomics, Inc. reported Total Revenue of $642.82 million for fiscal year 2025.
- 10x Genomics, Inc. showed an increase of +5.2% in Total Revenue compared to the prior fiscal year.
- 10x Genomics, Inc. reported Revenue (ASC 606) of $642.82 million for fiscal year 2025.
- 10x Genomics, Inc. showed an increase of +5.2% in Revenue (ASC 606) compared to the prior fiscal year.
- 10x Genomics, Inc. reported Net Income of -$43.54 million for fiscal year 2025.
- 10x Genomics, Inc. showed an increase of +76.2% in Net Income compared to the prior fiscal year.
- 10x Genomics, Inc. reported Diluted EPS of $0.35 per share (loss) for fiscal year 2025.
- 10x Genomics, Inc. showed an increase of +77.0% in Diluted EPS compared to the prior fiscal year.
- 10x Genomics, Inc. reported Total Assets of $1.04 billion for fiscal year 2025.
- 10x Genomics, Inc. showed an increase of +13.4% in Total Assets compared to the prior fiscal year.
- 10x Genomics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2020.
- 10x Genomics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- 10x Genomics, Inc. reported Stockholders Equity of $796.33 million for fiscal year 2025.
- 10x Genomics, Inc. showed an increase of +12.1% in Stockholders Equity compared to the prior fiscal year.
- 10x Genomics, Inc. reported Operating Income of -$60.98 million for fiscal year 2025.
- 10x Genomics, Inc. showed an increase of +68.7% in Operating Income compared to the prior fiscal year.
- 10x Genomics, Inc. reported Gross Profit of $443.88 million for fiscal year 2025.
- 10x Genomics, Inc. showed an increase of +7.1% in Gross Profit compared to the prior fiscal year.
- 10x Genomics, Inc. reported Shares Outstanding of 127.69 million shares for fiscal year 2025.
- 10x Genomics, Inc. showed an increase of +4.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: